Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis

Ankit Bharat, Kishore Narayanan, Anjali Golocheikine, Nancy Steward, Jeffrey Crippin, Mauricio Lisker-Melman, Surendra Shenoy, Jeffrey Lowell, William C. Chapman, Thalachallour Mohanakumar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-γ and high frequency of IFN-γ producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.

Original languageEnglish (US)
Pages (from-to)1704-1707
Number of pages4
Issue number12
StatePublished - Dec 2007


  • Hepatitis C virus
  • Liver transplantation
  • Soluble CD30

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis'. Together they form a unique fingerprint.

Cite this